How many institutions own DRMA stock?

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own DRMA shares is 11, representing 7.38% of the company's common stock.

Who are the major shareholders selling Dermata Therapeutics, Inc. stock?

CLEAR STREET GROUP INC., in the last quarter, reduced its stake in DRMA by -100% restricting it's holding to 0 shares of worth nearly -. TOWER RESEARCH CAPITAL LLC (TRC) also lessened -64.18% of the DRMA shares from its portfolio, reducing its holding to 716 shares of worth $866.00. JPMORGAN CHASE & CO also shunned DRMA shares holding by -100% last quarter which brought its holding to 0 shares worth -.

Investors who are buying DRMA stock?

As per its latest 13F filing, GEODE CAPITAL MANAGEMENT, LLC increased its stake in DRMA by 100% in the last quarter. The institutional holder raised its holding to 48.33 thousand shares having worth more than $58.48K. UBS GROUP AG also added 2,778.58% more shares of DRMA to its portfolio, raising its holding to 35.61 thousand shares of worth $43.09K. WELCH & FORBES LLC also increased its DRMA shares holding by 100% which brought its holding to 20 thousand shares worth $24.20K.

DRMA's major insiders: who are they?

The insider with the most stakes in DRMA is PROEHL GERALD T , President, CEO and Chairman at the company. Additionally, DRMA stock is highly held by director HALE DAVID F and SVP, Regulatory Affairs Bedoya-Toro Munera Maria E among others.

Did an insider recently sell DRMA stock?

Company executives, directors, and other insiders own 24.82% percent of Dermata Therapeutics, Inc.'s stock. Within the last six months, there have been 1 transaction(s) in which DRMA insiders have sold stock, totaling 11 shares. Insiders that have sold shares include SCOTT KATHLEEN D..

Which insider recently purchased DRMA stock?

There have been 1 transaction(s) during the past 6-months in which Dermata Therapeutics, Inc. insiders have bought stock, totalling 1000 shares

How much of DRMA does insiders own?

Around 1.01K Dermata Therapeutics, Inc. shares are held by insiders, which represents about 24.82% of DRMA stock.

Who is the insider with the largest stake?

DRMA President, CEO and Chairman, PROEHL GERALD T holds the largest portfolio of the company's shares. DRMA shares owned by PROEHL total nearly 59.51 thousand.

Which institution holds the most shares in DRMA?

CLEAR STREET GROUP INC. is the largest institutional owner in DRMA which holds 0 shares worth - or 0% of the total DRMA shares outstanding followed by GEODE CAPITAL MANAGEMENT, LLC with ownership of 48.33 thousand shares representing 1.25% of the DRMA ownership. UBS GROUP AG is the third largest stakeholder with 35.61 thousand shares or 0.92% of the ownership worth more than $43.09K.

Is Dermata Therapeutics, Inc. stock optionable?

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the DRMA is concerned, it is a stock which is not optionable.

Is there a short position on DRMA's shares?

Number of DRMA shares short is 64.86K. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

About how many outstanding DRMA shares are there?

As of today, 4.02M shares of DRMA are outstanding.

Is there many float in DRMA stock?

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, DRMA has 3.17M shares in float.

DRMA short ratio: what is it?

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for DRMA is 0.68.

Dermata Therapeutics (DRMA) insider trading activity: Get Latest News Today

Stock Outstanding Shares

Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.

ShortableYes

OptionableNo

Short Percent Of Outstanding Shares1.61

Short Percent Of Float2.06

Shares Outstanding4.02M

Shares Float3.17M

Shares Short64.86K

Short Ratio0.68

2.06%

Short % of Float

1.61%

Short % of Shares Outstanding

Market Insider

Investors cannot turn a blind eye to insiders as well as institutional ownership. They need to follow insider trades to determine the direction the stock is likely to take.

Major Holders Summary

24.82% Percentage of Shares held by All Insiders

7.38% Percentage of Shares held by All Institutions

9.81% Percentage of Float held by Institutions

Number of Institutions Holding Shares

Institutional Ownership

About 7.38% of DRMA shares are held by financial institutions. CLEAR STREET GROUP INC. is the top corporate investor, holding 0 shares valued at -. A 0% stake in Dermata Therapeutics, Inc. is owned by the company. GEODE CAPITAL MANAGEMENT, LLC owns 48.33K shares valued at $58.48K, which translates its holding of 1.25% of the stake in the company.

Date	Holder	% Stake	Shares Held	Total Value ($)	Shares	% Change in Portfolio
Mar 31, 2026	CLEAR STREET GROUP INC.	0%	0	-	-17K	-100.00%
Mar 31, 2026	GEODE CAPITAL MANAGEMENT, LLC	1.25%	48.33K	58.48K	48.33K	+100.00%
Mar 31, 2026	UBS GROUP AG	0.92%	35.61K	43.09K	34.37K	+2,778.58%
Mar 31, 2026	WELCH & FORBES LLC	0.52%	20K	24.2K	20K	+100.00%
Mar 31, 2026	MCF ADVISORS LLC	0.04%	1.73K	2.1K	1.73K	+100.00%
Mar 31, 2026	TOWER RESEARCH CAPITAL LLC (TRC)	0.02%	716	866	-1.28K	-64.18%
Mar 31, 2026	SBI SECURITIES CO., LTD.	0%	101	122	0	0
Mar 31, 2026	CITIGROUP INC	0%	1	1	1	+100.00%
Mar 31, 2026	JPMORGAN CHASE & CO	0%	0	-	-696	-100.00%
Mar 31, 2026	BANK OF AMERICA CORP /DE/	0%	0	-	-3.46K	-100.00%
Mar 31, 2026	BARCLAYS PLC	0%	0	-	-2.4K	-100.00%
Mar 31, 2023	GEODE CAPITAL MANAGEMENT, LLC	0%	0	-	-26.67K	-100.00%
Mar 31, 2023	MORGAN STANLEY	0%	0	-	-562	-100.00%
Mar 31, 2023	TWO SIGMA SECURITIES, LLC	0%	0	-	-12.43K	-100.00%
Mar 31, 2023	RAYMOND JAMES FINANCIAL SERVICES ADVISORS, INC.	0%	0	-	-141.76K	-100.00%
Mar 31, 2023	TUDOR INVESTMENT CORP ET AL	0%	0	-	-10.21K	-100.00%
Mar 31, 2023	TOWER RESEARCH CAPITAL LLC (TRC)	0%	0	-	-4.69K	-100.00%
Mar 31, 2023	FAS WEALTH PARTNERS, INC.	0%	0	-	-12.7K	-100.00%
Mar 31, 2023	UBS GROUP AG	0%	0	-	-37.31K	-100.00%
Mar 31, 2023	SAGE CAPITAL ADVISORS,LLC	0%	0	-	-12K	-100.00%
Mar 31, 2023	HC ADVISORS, LLC	0%	0	-	-10K	-100.00%
Mar 31, 2023	WELLS FARGO & COMPANY/MN	0%	0	-	-24.44K	-100.00%
Mar 31, 2023	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	0%	0	-	0	0
Dec 31, 2022	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	0%	0	-	0	0
Dec 31, 2022	JANE STREET GROUP, LLC	0%	0	-	-23.57K	-100.00%
Dec 31, 2022	TOWER RESEARCH CAPITAL LLC (TRC)	0.03%	4.69K	2K	-84	-1.76%
Dec 31, 2022	WELLS FARGO & COMPANY/MN	0.15%	24.44K	10K	20	+0.08%
Dec 31, 2022	UBS GROUP AG	4.86%	37.31K	15.3K	22.51K	+152.12%
Dec 31, 2022	GEODE CAPITAL MANAGEMENT, LLC	3.48%	26.67K	10K	0	0
Dec 31, 2022	FMR LLC	0%	0	-	-10K	-100.00%
Dec 31, 2022	FAS WEALTH PARTNERS, INC.	1.65%	12.7K	5.19K	12.7K	+100.00%
Dec 31, 2022	TWO SIGMA SECURITIES, LLC	1.62%	12.43K	5.09K	12.43K	+100.00%
Dec 31, 2022	RAYMOND JAMES FINANCIAL SERVICES ADVISORS, INC.	0.9%	141.76K	57.98K	141.76K	+100.00%
Dec 31, 2022	SAGE CAPITAL ADVISORS,LLC	0.08%	12K	4.91K	0	0
Dec 31, 2022	HC ADVISORS, LLC	0.06%	10K	4.09K	10K	+100.00%
Dec 31, 2022	MORGAN STANLEY	0%	562	230	562	+100.00%
Dec 31, 2022	VIRTU FINANCIAL LLC	0%	0	-	-70.81K	-100.00%
Dec 31, 2022	TUDOR INVESTMENT CORP ET AL	1.33%	10.21K	4K	0	0

Insiders

Among the DRMA insiders holding of 24.82% of the stake in company, PROEHL GERALD T, President, CEO and Chairman, holds the largest shares of 59.51K. HALE DAVID F, director, is the second largest DRMA insider with ownership of 35.71K shares. BEDOYA-TORO MUNERA MARIA E, SVP, Regulatory Affairs, stands third with possession of 1.01K shares of that stake.

Insiders	Designation	Shares Held
PROEHL GERALD T	President, CEO and Chairman	59.51K
HALE DAVID F	director	35.71K
BEDOYA-TORO MUNERA MARIA E	SVP, Regulatory Affairs	1.01K
SCOTT KATHLEEN D.	director	0

Buying/Selling by Insiders

Date	Insider	Type	Cost	Shares	Value ($)	Shares Total
Jun 16, 2026	SCOTT KATHLEEN D.	SALE	1.19	11	13.09	0
Feb 17, 2026	BEDOYA-TORO MUNERA MARIA E	PURCHASE	1.27	1K	1.27K	1.01K
Nov 23, 2021	PROEHL GERALD T	PURCHASE	2.40	20K	48K	59.51K
Aug 17, 2021	HALE DAVID F	PURCHASE	7.00	35.71K	250K	35.71K
Aug 16, 2021	PROEHL GERALD T	PURCHASE	4.96	10K	49.63K	10K

Insider Transaction Summary (6 Months)

SHARESTRANS

PURCHASE1K1

SALES111

NET SHARES9890

SHARES HELD1.01K2

% NET SHARES-2.27%-100%

DRMA Stock Ownership Breakdown